Want to see JAZZ full AI Analyst Report?
Neroscience Revenue Breakdown
Highlights revenue generated from neuroscience products, indicating the company's strength and focus in treating neurological disorders, and potential growth in this specialized market.Xywav has taken over as the growth engine in sleep, largely replacing steeply eroding Xyrem sales and driving overall revenue expansion, a trend management confirmed with patient adds and mid‑teens growth; Epidiolex is a steady second pillar with durable double‑digit volume gains. Sunosi revenues have effectively exited the portfolio. The company’s pivot to newer sleep, epilepsy and oncology products improves upside but creates near‑term margin and competitive risk as management warned of H2 generic/wake‑promoter pressure and ongoing IP/litigation exposure.
Date | Xywav | Xyrem | Epidiolex | Sativex | Sunosi |
|---|---|---|---|---|---|
Jun 30, 2026 | $471.20M | $30.50M | $292.10M | $0.00 | $0.00 |
Mar 31, 2026 | $408.20M | $31.20M | $249.80M | $0.00 | $0.00 |
Dec 31, 2025 | $465.45M | $37.78M | $287.12M | $1.50M | $0.00 |
Sep 30, 2025 | $431.41M | $35.66M | $302.61M | $4.75M | $0.00 |
Jun 30, 2025 | $415.32M | $35.35M | $251.73M | $4.62M | $0.00 |
Mar 31, 2025 | $344.80M | $37.24M | $217.74M | $5.41M | $0.00 |
Dec 31, 2024 | $400.96M | $49.29M | $275.05M | $5.17M | $0.00 |
Sep 30, 2024 | $388.47M | $58.11M | $251.56M | $4.59M | $0.00 |
Jun 30, 2024 | $368.47M | $62.18M | $247.10M | $6.38M | $0.00 |
Mar 31, 2024 | $315.30M | $64.23M | $198.72M | $2.73M | $0.00 |